Press Releases

Filters (1)
June 9, 2020

Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

Read more
January 8, 2020

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

Read more
June 12, 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Read more
January 7, 2019

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Read more
October 3, 2017

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

Read more
June 30, 2017

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…

Read more
January 9, 2017

Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe

Read more
January 13, 2016

Debiopharm International SA and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers

Read more
January 11, 2016

Debiopharm International SA and Arbor Pharmaceuticals, LLC announce their US commercialization partnership for Triptorelin in Central Precocious Puberty

Read more